⌕
Biomarin Pharmaceutical · BMRN · Nasdaq
Tenet 43 · Weak
Compare
$58.51+0.90%At closeTenet 43 · Weak
$58.51+0.52 (+0.90%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Biomarin Pharmaceutical (BMRN) Stock

Biomarin Pharmaceutical (BMRN) closed at $58.51 on Nov 17, 2026; its Tenet Score is 43 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

6 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$58.51
Nov 17, 2026
Market cap
$11.2B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
49.26 – 70.98
low → high · as of close, Nov 16, 2026
Tenet Score
43/100
Weak · 340 Healthcare peers

Industry: Drugs

Biomarin Pharmaceutical Inc. scores 43/100. Weak. Financial health is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
43/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
41
Quality
51
Health
22
Growth
59

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityCHealthFGrowthCMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
1.8×
Sep 30, 2026 balance sheet
P/S
3.1×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
0%
TTM through Sep 30, 2026
Operating margin
12.7%
fiscal 2025, before interest and tax
Net margin
−0.5%
TTM through Sep 30, 2026
Current ratio
2.44
Sep 30, 2026 balance sheet
Net debt / EBITDA
8.5×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Biomarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysacchar…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 176 US ETFs · top wrappers by weightSee all ETFs holding BMRN →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Biomarin Pharmaceutical in?

Biomarin Pharmaceutical is in the Healthcare sector and the Drugs industry.

What is Biomarin Pharmaceutical's Tenet Score?

Biomarin Pharmaceutical's Tenet Score is 43 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.